Mr Braccia brings over 20 years of deal and operating experience to Myeloid Therapeutics. In this new role he will collaborate with the Myeloid team, to identify, evaluate, and select external partners for our assets, and more broadly to implement growth scenarios for Myeloid, while also supporting the day-to-day affairs of our growing business.
With past professional experiences spanning the research, development and commercialization of therapeutics (Biogen, Vertex), along with general management of several private companies at similar early-stages (Lysosomal Therapeutics, sold to Bial; Magellan Bio assets sold to Thermo Fisher and Meridian Biosciences), he will be an integral member of the Myeloid team.
We welcome the opportunity to gain from his perspective built from professional experience across all aspects of corporate and business development. He has played instrumental roles in guiding team decision-making and new product development for programs and assets in orphan diseases, oncology, infectious diseases, inflammation, and most recently, in neurodegeneration. His breadth of experience, at successful public and private healthcare product companies, will complement the Myeloid team with leadership, strategy setting and execution, new product development, and partnering/financing. Mr Braccia is a graduate of the J.L. Kellogg Graduate School of Management at Northwestern University, and Washington and Lee University, and active in service to his community.